Positioning ustekinumab in Crohn's disease: From clinical evidence to clinical practice

Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet

Research output: Contribution to journalReview articlepeer-review


Biological medicines have revolutionised the treatment of Crohn's disease [CD]. Yet, the management of patients not responding to tumour necrosis factor [TNF] antagonists remains a clinical challenge. Ustekinumab is a human monoclonal antibody blocking the biological activity of interleukins 12 and 23, which regulate the immune system and immune-mediated inflammatory disorders. Ustekinumab has recently been approved for the treatment of adult patients with moderately to severely active CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist, or have medical contraindications to such therapies. Herein, we review the new biological drug's efficacy and safety data reported from randomised controlled trials and real-world observational studies conducted in populations with CD, in order to identify the patient groups most likely to benefit, and to appropriately place ustekinumab into treatment algorithms for CD.

Original languageEnglish
Pages (from-to)1258-1266
Number of pages9
JournalJournal of Crohn's and Colitis
Issue number10
Publication statusPublished - Oct 1 2017


  • Crohn's disease
  • Ustekinumab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Positioning ustekinumab in Crohn's disease: From clinical evidence to clinical practice'. Together they form a unique fingerprint.

Cite this